ARTV Artiva Biotherapeutics, Inc.

NASDAQ
$3.96

Artiva Biotherapeutics, Inc. (ARTV) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.7% since its last earnings release on November 9, 2026.

Artiva Biotherapeutics Missed Consensus Estimates
Monday, November 9, 2026 · 12:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.56)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.03

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.